Mohammed Shoaib1. 1. Psychobiology Research Laboratories, Newcastle Medical School, Newcastle University, Newcastle, NE2 4HH, UK. mohammed.shoaib@newcastle.ac.uk
Abstract
RATIONALE: The nicotinic receptor agonist, isoarecolone, has 'nicotine-like' subjective properties as detected by rats in a discrimination paradigm. However, isoarecolone lacks the intra-accumbens dopamine-releasing effects, a feature akin to most abused substances. In the five-choice serial reaction time task, isoarecolone can enhance attention and thus may be developed as a cognitive enhancer. OBJECTIVE: The present experiments assess the dependence profile of isoarecolone in rodent models of nicotine dependence. METHOD AND RESULTS: Tests for cross-substitution in which isoarecolone is substituted for nicotine [0.3 mg/kg/infusion (inf)] self-administration suggest isoarecolone to have nominal reinforcing properties (0.3 or 1.0 mg/kg/inf); intake of isoarecolone declined over three test sessions in which responding was no different from saline extinction, and behaviour was reinstated by re-presenting nicotine. In a model of nicotine-seeking behaviour, rats having been extinguished by removal of nicotine (0.03 mg/kg/inf) and associated cues, the presentation of priming doses of nicotine (0.1-0.4 mg/kg s.c.) with the cues robustly reinstated responding of nicotine-seeking behaviour. Tests with priming doses of isoarecolone (1-20 mg/kg s.c.) shown previously to generalise to nicotine in discrimination tests produced significant levels of reinstatement but the responses were significantly less compared to nicotine-induced reinstatement. CONCLUSION: Overall, these results suggest that isoarecolone with its unique profile of behavioural activity should be further examined for treating chronic diseases that are characterised by attentional dysfunction.
RATIONALE: The nicotinic receptor agonist, isoarecolone, has 'nicotine-like' subjective properties as detected by rats in a discrimination paradigm. However, isoarecolone lacks the intra-accumbens dopamine-releasing effects, a feature akin to most abused substances. In the five-choice serial reaction time task, isoarecolone can enhance attention and thus may be developed as a cognitive enhancer. OBJECTIVE: The present experiments assess the dependence profile of isoarecolone in rodent models of nicotine dependence. METHOD AND RESULTS: Tests for cross-substitution in which isoarecolone is substituted for nicotine [0.3 mg/kg/infusion (inf)] self-administration suggest isoarecolone to have nominal reinforcing properties (0.3 or 1.0 mg/kg/inf); intake of isoarecolone declined over three test sessions in which responding was no different from saline extinction, and behaviour was reinstated by re-presenting nicotine. In a model of nicotine-seeking behaviour, rats having been extinguished by removal of nicotine (0.03 mg/kg/inf) and associated cues, the presentation of priming doses of nicotine (0.1-0.4 mg/kg s.c.) with the cues robustly reinstated responding of nicotine-seeking behaviour. Tests with priming doses of isoarecolone (1-20 mg/kg s.c.) shown previously to generalise to nicotine in discrimination tests produced significant levels of reinstatement but the responses were significantly less compared to nicotine-induced reinstatement. CONCLUSION: Overall, these results suggest that isoarecolone with its unique profile of behavioural activity should be further examined for treating chronic diseases that are characterised by attentional dysfunction.
Authors: Maria E Secci; Alessia Auber; Leigh V Panlilio; Godfrey H Redhi; Eric B Thorndike; Charles W Schindler; Robert Schwarcz; Steven R Goldberg; Zuzana Justinova Journal: Neuropsychopharmacology Date: 2017-01-31 Impact factor: 7.853
Authors: Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado Journal: Neurosci Biobehav Rev Date: 2010-02-16 Impact factor: 8.989
Authors: Paola Mascia; Marco Pistis; Zuzana Justinova; Leigh V Panlilio; Antonio Luchicchi; Salvatore Lecca; Maria Scherma; Walter Fratta; Paola Fadda; Chanel Barnes; Godfrey H Redhi; Sevil Yasar; Bernard Le Foll; Gianluigi Tanda; Daniele Piomelli; Steven R Goldberg Journal: Biol Psychiatry Date: 2011-04-01 Impact factor: 13.382
Authors: Nicole A Horenstein; Marta Quadri; Clare Stokes; Mohammed Shoaib; Roger L Papke Journal: Nicotine Tob Res Date: 2019-05-21 Impact factor: 4.244
Authors: Aliou B Gueye; Yaroslaw Pryslawsky; Jose M Trigo; Nafsika Poulia; Foteini Delis; Katerina Antoniou; Michael Loureiro; Steve R Laviolette; Kiran Vemuri; Alexandros Makriyannis; Bernard Le Foll Journal: Int J Neuropsychopharmacol Date: 2016-12-30 Impact factor: 5.176
Authors: Maria Scherma; Paola Fadda; Bernard Le Foll; Benoit Forget; Walter Fratta; Steven R Goldberg; Gianluigi Tanda Journal: CNS Neurol Disord Drug Targets Date: 2008-11 Impact factor: 4.388